Understand the source comparison
Autoimmune Peptides 2026 Update: Mechanism Comparison
Thymosin Alpha-1 TLR9 agonism → Treg differentiation, Th17 suppression Toll-like receptor 9 Rheumatoid arthritis, lupus, Crohn's disease Phase III completed Strongest evidence base for multi-system autoimmune disease; dual pathway makes it difficult to predict
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR9 agonism → Treg differentiation, Th17 suppression
- Toll-like receptor 9
- Rheumatoid arthritis, lupus, Crohn's disease
- Phase III completed
- Strongest evidence base for multi-system autoimmune disease; dual pathway makes it difficult to predict individual response
- KPV Tripeptide
- MC1R activation → IL-10 production, NF-κB inhibition
- Melanocortin-1 receptor
- Ulcerative colitis, psoriasis
- FDA fast-track designation
- Most effective for localised autoimmune conditions; oral bioavailability requires enteric coating
- BT-11 (IL-10 mimetic)
- Partial IL-10Rα agonism → STAT3/SOCS3 activation
- IL-10 receptor alpha
- Systemic lupus, rheumatoid arthritis, Crohn's
- Phase III ongoing
- Breakthrough efficacy in lupus trials; expensive to manufacture limits accessibility
- Thymosin Beta-4
- Actin sequestration → reduced T-cell migration
- G-actin binding
- Lupus, multiple sclerosis
- Phase II completed
- Unique cytoskeletal mechanism; requires daily dosing for sustained effect
- LL-37 Fragment
- P2X7 antagonism → tolerogenic dendritic cell induction
- P2X7 purinergic receptor
- Psoriasis, ankylosing spondylitis
- Outperformed biologics in psoriasis trials; short half-life requires twice-daily dosing